Krista L Lanctôt, PhD

Dr. Krista Lanctôt leads a large interdisciplinary research team whose work has focused on understanding how neuropsychiatric symptoms, such a mild cognitive impairment and mood disorders, interfere with cardiac rehabilitation. The overarching theme of her work is to understand the neurobiologic basis of these symptoms as risk factors for poor response, and use this information to develop targeted interventions. For example, her work has shown links between these symptoms and inflammation, oxidative stress and lipid aberrations. Dr. Lanctôt's team uses a variety of tools including neuroimaging, lipidomics, pharmacogenetics and neuropsychiatric assessments to unravel the link between dysfunction in various cellular and molecular processes and manifestation of these symptoms in a cardiac rehabilitation population. In addition, her group has run clinical trials of dietary, pharmacologic and exercise interventions for these symptoms.

Each year tens of thousands of Canadians are diagnosed with coronary artery disease (CAD) which poses a serious risk to their health and well-being. Depression and associated symptoms of cognitive impairment are common neuropsychiatric symptoms in CAD and have a major negative impact on treatment outcomes and life expectancy. Dr. Lanctôt's work has also shown their negative impact on cardiac rehabilitation outcomes. Understanding the neurobiology of these symptoms may allow us to predict response to cardiac rehabilitation and, on a broader level, may lead to the development of novel therapies.
 
J Am Heart Assoc. 2018 May 05;7(10):
Chan P, Suridjan I, Mohammad D, Herrmann N, Mazereeuw G, Hillyer LM, Ma DWL, Oh PI, Lanctôt KL
Eur J Clin Microbiol Infect Dis. 2018 May 04;:
Mitchell I, Wong SK, Paes B, Ruff M, Bjornson C, Li A, Lanctôt KL, CARESS investigators
Cochrane Database Syst Rev. 2018 May 04;5:CD012197
Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL
Gen Hosp Psychiatry. 2018 Mar 23;52:41-47
Hawkins M, Schaffer A, Sinyor M, Nishikawa Y, Herrmann N, Lanctôt KL, Styra R, Pompili M, Huffman J
Eur J Clin Microbiol Infect Dis. 2018 Mar 19;:
Bjornson C, Chan P, Li A, Paes B, Lanctôt KL, Mitchell I
Curr Psychiatry Rep. 2018 Mar 12;20(3):16
Rapoport MJ, Chee JN, Carr DB, Molnar F, Naglie G, Dow J, Marottoli R, Mitchell S, Tant M, Herrmann N, Lanctôt KL, Taylor JP, Donaghy PC, Classen S, O'Neill D
Neurology. 2018 Jan 26;:
Swardfager W, Cogo-Moreira H, Masellis M, Ramirez J, Herrmann N, Edwards JD, Saleem M, Chan P, Yu D, Nestor SM, Scott CJM, Holmes MF, Sahlas DJ, Kiss A, Oh PI, Strother SC, Gao F, Stefanovic B, Keith J, Symons S, Swartz RH, Lanctôt KL, Stuss DT, Black SE
BMC Geriatr. 2018 Jan 25;18(1):27
Middleton LE, Black SE, Herrmann N, Oh PI, Regan K, Lanctot KL
Trials. 2018 Jan 18;19(1):46
Scherer RW, Drye L, Mintzer J, Lanctôt K, Rosenberg P, Herrmann N, Padala P, Brawman-Mintzer O, Burke W, Craft S, Lerner AJ, Levey A, Porsteinsson A, van Dyck CH, ADMET 2 Research Group
Curr Opin Psychiatry. 2017 Dec 18;:
Sherman C, Ruthirakuhan M, Vieira D, Lanctôt KL, Herrmann N

Pages


Senior Scientist, Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute
Director, Neuropsychopharmacology Research Program, Sunnybrook Health Science Centre
Professor, Department of Psychiatry, University of Toronto
Professor, Department of Pharmacology and Toxicology, University of Toronto
Full Member, School of Graduate Studies, University of Toronto
Executive Director, MORE research group, Sunnybrook Research Institute